Keywords: sanofi, ucb, enter, co-promotion, deal, xyzal, french
Sanofi and UCB enter US co-promotion deal for Xyzal
Article | 02 October 2006
French drug major Sanofi-Aventis and Belgium's UCB have entered into an agreement to co-promote Xyzal (levocetirizine dihydrochloride) in the USA. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
